Ultragenyx Pharmaceutical, Inc. (RARE)
16.27
-0.43
(-2.57%)
USD |
NASDAQ |
Nov 12, 16:00
16.04
-0.23
(-1.41%)
After-Hours: 05:45
Ultragenyx Pharmaceutical Free Cash Flow (Quarterly) : -45.00M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -45.00M |
| June 30, 2026 | -98.00M |
| March 31, 2026 | -203.00M |
| December 31, 2025 | -100.77M |
| September 30, 2025 | -92.70M |
| June 30, 2025 | -110.73M |
| March 31, 2025 | -182.80M |
| December 31, 2024 | -80.16M |
| September 30, 2024 | -68.61M |
| June 30, 2024 | -81.47M |
| March 31, 2024 | -203.94M |
| December 31, 2023 | -85.50M |
| September 30, 2023 | -121.57M |
| June 30, 2023 | -132.60M |
| March 31, 2023 | -181.90M |
| December 31, 2022 | -117.31M |
| September 30, 2022 | -121.39M |
| June 30, 2022 | -108.18M |
| March 31, 2022 | -179.70M |
| December 31, 2021 | -70.39M |
| September 30, 2021 | -80.21M |
| June 30, 2021 | -85.43M |
| March 31, 2021 | -175.76M |
| December 31, 2020 | -82.12M |
| September 30, 2020 | -68.02M |
| Date | Value |
|---|---|
| June 30, 2020 | 83.27M |
| March 31, 2020 | -109.25M |
| December 31, 2019 | -83.54M |
| September 30, 2019 | -93.54M |
| June 30, 2019 | -94.30M |
| March 31, 2019 | -98.83M |
| December 31, 2018 | -57.04M |
| September 30, 2018 | -70.19M |
| June 30, 2018 | -77.46M |
| March 31, 2018 | -89.95M |
| December 31, 2017 | -82.72M |
| September 30, 2017 | -63.03M |
| June 30, 2017 | -49.20M |
| March 31, 2017 | -61.69M |
| December 31, 2016 | -48.35M |
| September 30, 2016 | -31.75M |
| June 30, 2016 | -44.70M |
| March 31, 2016 | -46.37M |
| December 31, 2015 | -42.37M |
| September 30, 2015 | -32.58M |
| June 30, 2015 | -17.87M |
| March 31, 2015 | -18.12M |
| December 31, 2014 | -15.19M |
| September 30, 2014 | -11.47M |
| June 30, 2014 | -11.22M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | -193.63M |
| AbbVie, Inc. | 7.305B |
| Krystal Biotech, Inc. | 90.25M |
| BridgeBio Pharma, Inc. | -44.46M |
| Alnylam Pharmaceuticals, Inc. | 271.15M |